These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 24014028)
1. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028 [TBL] [Abstract][Full Text] [Related]
2. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047 [TBL] [Abstract][Full Text] [Related]
3. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein. Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984 [TBL] [Abstract][Full Text] [Related]
4. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073 [TBL] [Abstract][Full Text] [Related]
5. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. Li Z; Mei Y; Liu X; Zhou M Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839 [TBL] [Abstract][Full Text] [Related]
6. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway. Awasthi S; Hamburger AW J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179 [TBL] [Abstract][Full Text] [Related]
7. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850 [TBL] [Abstract][Full Text] [Related]
9. Homo- and Heteroassociations Drive Activation of ErbB3. Váradi T; Schneider M; Sevcsik E; Kiesenhofer D; Baumgart F; Batta G; Kovács T; Platzer R; Huppa JB; Szöllősi J; Schütz GJ; Brameshuber M; Nagy P Biophys J; 2019 Nov; 117(10):1935-1947. PubMed ID: 31653451 [TBL] [Abstract][Full Text] [Related]
10. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Choi BK; Fan X; Deng H; Zhang N; An Z Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251 [TBL] [Abstract][Full Text] [Related]
11. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929 [TBL] [Abstract][Full Text] [Related]
12. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232 [TBL] [Abstract][Full Text] [Related]
13. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Macdonald-Obermann JL; Piwnica-Worms D; Pike LJ Proc Natl Acad Sci U S A; 2012 Jan; 109(1):137-42. PubMed ID: 22190492 [TBL] [Abstract][Full Text] [Related]
14. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
16. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185 [TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Shin DH; Jo JY; Han JY Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202 [TBL] [Abstract][Full Text] [Related]
19. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504 [TBL] [Abstract][Full Text] [Related]
20. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]